cabozantinib-话题@MedSci

#cabozantinib#

25篇内容 | 1574人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1530333, encodeId=61451530333c2, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=J Immunother Cancer：Nivolumab(那武利尤单抗)联合cabozantinib(卡博替尼)治疗晚期子宫内膜癌患者的疗效, objectType=article, longId=300936, objectId=cbcd3009360c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbcd3009360c, replyNumber=0, likeNumber=70, createdTime=2022-03-18, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbcd3009360c, moduleTitle=J Immunother Cancer：Nivolumab(那武利尤单抗)联合cabozantinib(卡博替尼)治疗晚期子宫内膜癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbcd3009360c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530332, encodeId=7e43153033291, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=Clin Cancer Res：Cabozantinib（卡博替尼）单药治疗难治性软组织肉瘤(STS)的疗效和安全性, objectType=article, longId=291974, objectId=52c52919e488, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52c52919e488, replyNumber=0, likeNumber=112, createdTime=2021-12-18, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52c52919e488, moduleTitle=Clin Cancer Res：Cabozantinib（卡博替尼）单药治疗难治性软组织肉瘤(STS)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52c52919e488)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530331, encodeId=0c0c15303312e, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL, objectType=article, longId=221546, objectId=86b522154637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86b522154637, replyNumber=0, likeNumber=94, createdTime=2021-12-06, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86b522154637, moduleTitle=Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86b522154637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530330, encodeId=5df915303308b, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=Liver Cancer：卡博替尼（Cabozantinib）治疗晚期肝癌的疗效和安全性：来自国际多中心真实世界研究, objectType=article, longId=220567, objectId=10c022056e58, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10c022056e58, replyNumber=0, likeNumber=86, createdTime=2021-11-20, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10c022056e58, moduleTitle=Liver Cancer：卡博替尼（Cabozantinib）治疗晚期肝癌的疗效和安全性：来自国际多中心真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10c022056e58)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530329, encodeId=49191530329f0, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响, objectType=article, longId=219184, objectId=9df12191846b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9df12191846b, replyNumber=0, likeNumber=94, createdTime=2021-10-26, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9df12191846b, moduleTitle=The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9df12191846b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530328, encodeId=d1421530328bf, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=Eur J Cancer: 卡博替尼（Cabozantinib）治疗转移性肾细胞癌的疗效：来自真实世界研究CABOREAL结果分析, objectType=article, longId=219150, objectId=a7ac21915026, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7ac21915026, replyNumber=0, likeNumber=75, createdTime=2021-10-25, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7ac21915026, moduleTitle=Eur J Cancer: 卡博替尼（Cabozantinib）治疗转移性肾细胞癌的疗效：来自真实世界研究CABOREAL结果分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7ac21915026)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530327, encodeId=add4153032e8c, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=Br J Cancer：基于白蛋白胆红素（ALBI）分级评估卡博替尼（cabozantinib）治疗晚期肝细胞癌（HCC）的疗效和安全性, objectType=article, longId=218274, objectId=25462182e412, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25462182e412, replyNumber=0, likeNumber=85, createdTime=2021-10-10, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25462182e412, moduleTitle=Br J Cancer：基于白蛋白胆红素（ALBI）分级评估卡博替尼（cabozantinib）治疗晚期肝细胞癌（HCC）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25462182e412)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530326, encodeId=f6a215303261a, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=Liver Cancer：卡博替尼（Cabozantinib）治疗不可手术切除肝细胞癌的疗效和安全性：真实世界研究结果, objectType=article, longId=213115, objectId=9d6a213115e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d6a213115e4, replyNumber=0, likeNumber=80, createdTime=2021-06-25, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d6a213115e4, moduleTitle=Liver Cancer：卡博替尼（Cabozantinib）治疗不可手术切除肝细胞癌的疗效和安全性：真实世界研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d6a213115e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530325, encodeId=d526153032588, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=Liver Cancer：卡博替尼（Cabozantinib）治疗晚期肝癌的疗效和安全性：来自国际多中心真实世界研究, objectType=article, longId=212207, objectId=e1e021220e8c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1e021220e8c, replyNumber=0, likeNumber=60, createdTime=2021-06-04, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1e021220e8c, moduleTitle=Liver Cancer：卡博替尼（Cabozantinib）治疗晚期肝癌的疗效和安全性：来自国际多中心真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1e021220e8c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530324, encodeId=6b89153032479, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=NEJM：Nivolumab联合Cabozantinib治疗晚期肾细胞癌, objectType=article, longId=207911, objectId=9b3720e91188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b3720e91188, replyNumber=0, likeNumber=94, createdTime=2021-03-07, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b3720e91188, moduleTitle=NEJM：Nivolumab联合Cabozantinib治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b3720e91188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530323, encodeId=d8581530323e2, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见, objectType=article, longId=207706, objectId=989b20e706d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=989b20e706d8, replyNumber=0, likeNumber=83, createdTime=2021-03-01, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=989b20e706d8, moduleTitle=Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=989b20e706d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530322, encodeId=74b9153032233, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）, objectType=article, longId=207196, objectId=04c620e196a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04c620e196a7, replyNumber=0, likeNumber=65, createdTime=2021-02-18, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04c620e196a7, moduleTitle=ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04c620e196a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530321, encodeId=370e153032174, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=Nat Med：卡博替尼（cabozantinib）对于丛状神经纤维瘤的疗效, objectType=article, longId=205914, objectId=b6f9205914be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6f9205914be, replyNumber=0, likeNumber=68, createdTime=2021-01-21, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6f9205914be, moduleTitle=Nat Med：卡博替尼（cabozantinib）对于丛状神经纤维瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6f9205914be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530320, encodeId=e8441530320ba, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=日本批准CABOMETYX（cabozantinib）治疗无法切除的或转移性肾细胞癌, objectType=article, longId=190852, objectId=502a190852b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=502a190852b7, replyNumber=0, likeNumber=68, createdTime=2020-03-27, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=502a190852b7, moduleTitle=日本批准CABOMETYX（cabozantinib）治疗无法切除的或转移性肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=502a190852b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530319, encodeId=270e153031980, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=Clinical Cancer Res：Cabozantinib联合ADT治疗激素幼稚性转移性前列腺癌, objectType=article, longId=189552, objectId=e06a189552a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e06a189552a1, replyNumber=0, likeNumber=56, createdTime=2020-03-10, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e06a189552a1, moduleTitle=Clinical Cancer Res：Cabozantinib联合ADT治疗激素幼稚性转移性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e06a189552a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530318, encodeId=eb40153031817, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=晚期肝细胞癌：Cabozantinib、Nivolumab和Ipilimumab的三联疗法具有显著优势, objectType=article, longId=186743, objectId=96bb186e4389, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96bb186e4389, replyNumber=0, likeNumber=40, createdTime=2020-01-27, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96bb186e4389, moduleTitle=晚期肝细胞癌：Cabozantinib、Nivolumab和Ipilimumab的三联疗法具有显著优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96bb186e4389)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530317, encodeId=ab64153031e56, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=Cabozantinib与舒尼替尼作为中度或低风险转移性肾细胞癌的最佳治疗方案（Alliance A031203 CABOSUN随机试验）：总生存期和无进展生存, objectType=article, longId=136870, objectId=65ff1368e0d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65ff1368e0d9, replyNumber=0, likeNumber=115, createdTime=2018-05-01, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65ff1368e0d9, moduleTitle=Cabozantinib与舒尼替尼作为中度或低风险转移性肾细胞癌的最佳治疗方案（Alliance A031203 CABOSUN随机试验）：总生存期和无进展生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65ff1368e0d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530316, encodeId=41b81530316af, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=ANN ONCOL：cabozantinib治疗甲状腺髓样癌患者总生存分析, objectType=article, longId=121893, objectId=01e312189326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01e312189326, replyNumber=0, likeNumber=81, createdTime=2017-12-02, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01e312189326, moduleTitle=ANN ONCOL：cabozantinib治疗甲状腺髓样癌患者总生存分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01e312189326)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530315, encodeId=d0031530315e9, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=Lancet Oncol：晚期肾癌VEGF靶向治疗进展后， cabozantinib成新标准？, objectType=article, longId=108931, objectId=e67710893136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e67710893136, replyNumber=0, likeNumber=68, createdTime=2017-08-17, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e67710893136, moduleTitle=Lancet Oncol：晚期肾癌VEGF靶向治疗进展后， cabozantinib成新标准？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e67710893136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1530314, encodeId=0aa6153031430, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, objectTitle=Eur J Cancer：Cabozantinib治疗卵巢癌的有效（随机停药试验）, objectType=article, longId=107323, objectId=98ca10e32337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98ca10e32337, replyNumber=0, likeNumber=73, createdTime=2017-08-02, rootId=0, userName=zhao4620, userId=a95b12086600, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98ca10e32337, moduleTitle=Eur J Cancer：Cabozantinib治疗卵巢癌的有效（随机停药试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98ca10e32337)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

cabozantinib

2020-05-29

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

J Immunother Cancer：Nivolumab(那武利尤单抗)联合cabozantinib(卡博替尼)治疗晚期子宫内膜癌患者的疗效

2022-03-18

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

Clin Cancer Res：Cabozantinib（卡博替尼）单药治疗难治性软组织肉瘤(STS)的疗效和安全性

2021-12-18

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

Liver Cancer：卡博替尼（Cabozantinib）对比安慰剂治疗晚期肝细胞癌患者的基于血清标志物的预后分析：3期临床研究CELESTIAL

2021-12-06

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

Liver Cancer：卡博替尼（Cabozantinib）治疗晚期肝癌的疗效和安全性：来自国际多中心真实世界研究

2021-11-20

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响

2021-10-26

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

Eur J Cancer: 卡博替尼（Cabozantinib）治疗转移性肾细胞癌的疗效：来自真实世界研究CABOREAL结果分析

2021-10-25

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

Br J Cancer：基于白蛋白胆红素（ALBI）分级评估卡博替尼（cabozantinib）治疗晚期肝细胞癌（HCC）的疗效和安全性

2021-10-10

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

Liver Cancer：卡博替尼（Cabozantinib）治疗不可手术切除肝细胞癌的疗效和安全性：真实世界研究结果

2021-06-25

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

Liver Cancer：卡博替尼（Cabozantinib）治疗晚期肝癌的疗效和安全性：来自国际多中心真实世界研究

2021-06-04

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

NEJM：Nivolumab联合Cabozantinib治疗晚期肾细胞癌

2021-03-07

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见

2021-03-01

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）

2021-02-18

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

Nat Med：卡博替尼（cabozantinib）对于丛状神经纤维瘤的疗效

2021-01-21

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

日本批准CABOMETYX（cabozantinib）治疗无法切除的或转移性肾细胞癌

2020-03-27

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

Clinical Cancer Res：Cabozantinib联合ADT治疗激素幼稚性转移性前列腺癌

2020-03-10

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

晚期肝细胞癌：Cabozantinib、Nivolumab和Ipilimumab的三联疗法具有显著优势

2020-01-27

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

Cabozantinib与舒尼替尼作为中度或低风险转移性肾细胞癌的最佳治疗方案（Alliance A031203 CABOSUN随机试验）：总生存期和无进展生存

2018-05-01

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

ANN ONCOL：cabozantinib治疗甲状腺髓样癌患者总生存分析

2017-12-02

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

Lancet Oncol：晚期肾癌VEGF靶向治疗进展后， cabozantinib成新标准？

2017-08-17

zhao4620 (审核中...)

前往app查看评论内容

#cabozantinib#

Eur J Cancer：Cabozantinib治疗卵巢癌的有效（随机停药试验）

2017-08-02

科室
- - 订阅+
  - 更多科室
工具
服务